Progyny, Inc. (PGNY): debt financing — Progyny enters $200M credit facility; Q2 results expected slightly above guidance

Progyny, Inc.

Entered $200M revolving credit facility maturing July 1, 2030; undrawn at closing.
Facility secured by substantially all assets; variable interest based on SOFR or base rate plus margin.
Q2 2025 revenue, Adjusted net income, and Adjusted EBITDA expected slightly above prior guidance.
Company has no planned use for facility; capital priorities (buybacks, product expansion, acquisitions) unchanged.
JPMorgan Chase Bank acts as administrative agent.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Progyny, Inc. incurred revolving credit of $200.0 million with JPMorgan Chase Bank, N.A., as administrative agent, collateral agent, and swingline lender at adjusted SOFR, or the alternate base rate, plus, in each case, an applicable mar maturing July 1, 2030.

Instrument: revolving credit
Principal: $200.0 million
Counterparty: JPMorgan Chase Bank, N.A., as administrative agent, collateral agent, and swingline lender
Rate: adjusted SOFR, or the alternate base rate, plus, in each case, an applicable mar
Maturity: July 1, 2030
Event: incurrence

Exact text from the filing

but not defined herein shall have the meanings assigned to such terms in the Credit Agreement. The Credit Agreement makes available to the Company a maximum aggregate amount of $200.0 million of revolving loan commitments, which may be drawn, subject to customary borrowing conditions, until maturity on July 1, 2030. Subject to certain conditions, the Company may at

View on SEC.gov

Browse all debt financings →

Progyny, Inc. filing history →

Source: SEC EDGAR

accession 0001551306-25-000153

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.